Search PubMed⌕ Search

Biomedical subjects

S Goldfarb

Publications and source records attributed to S Goldfarb.

At least 73 records · Page 4Linked to original sources
PubMed1986

The acute and chronic effects of indoramin on renal function, hemodynamics, and transport.

The acute and chronic renal effects of indoramin, an alpha 1-adrenoceptor antagonist, were investigated in six normotensive men (mean +/- SEM age, 36 +/- 3 years). Renal clearance studies were done during steady-state water diuresis before administration of indoramin (baseline), 3-4 h after a single 50-mg oral dose (acute study), and after 7 days of treatment with 25 mg twice daily (chronic study). After a single 50-mg oral dose, mean supine blood pressure decreased from 117/76 mm Hg at baseline to 109/74 mm Hg (NS), and glomerular filtration rate and renal blood flow were unchanged. There were small decreases (0.05 less than p less than 0.1) in the fractional excretion of sodium and potassium. After chronic administration (7 days) of indoramin, no significant changes in blood pressure, renal function, renal hemodynamics, or fluid and electrolyte excretion were observed. Mean body weight tended to decrease and fractional sodium excretion increased slightly (NS) after 7 days of indoramin. Plasma renin and aldosterone concentrations tended to increase (NS) after chronic indoramin administration. The results of this study indicate that acute and chronic administration of indoramin does not adversely affect renal function, renal hemodynamics, or fluid and electrolyte excretion in normotensive subjects.

Administration, Oral↗
PubMed1986

In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.

The effects of WR-2721 [S-2-(3-aminopropylaminoethyl)phosphorothioic acid] in two in vivo and in vitro models of experimental hypercalcemia in the rat were examined. Chronic WR-2721 administration by osmotic minipump (250 mg/kg/24 hr) reduced serum calcium from 12.0 +/- 0.1 to 9.5 +/- 1.0 mg/dl (P less than .01) in rats receiving 1,25-(OH)2 Vitamin D3. Control rats receiving Vitamin D without WR-2721 had a rise in serum calcium to 13.4 +/- 0.2 mg/dl over the same 5-day period. In an experimental form of humoral hypercalcemia of malignancy, the Walker carcinosarcoma tumor-implanted rat, WR-2721 reduced serum calcium from 13.6 +/- 0.3 to 8.4 +/- 0.6 mg/dl by 5 to 6 days (P less than .001). In vitro bone resorption assays utilizing fetal rat long bones in organ culture showed complementary results. WR-2721 (10(-4) M) blocked bone resorption (assayed as percentage of 45Ca release) induced by both conditioned medium derived from cell lines of Walker carcinosarcoma (7.6 +/- 1.4 vs. 24.0 +/- 1.8%, P less than .01) and by addition of 1,25-(OH)2 Vitamin D3 (10(-8) M) (9.8 +/- 0.8 vs. 17.3 +/- 1.0%, P less than .01). These results suggest that WR-2721 may be effective in controlling clinical hypercalcemia due to excess bone resorption.

Amifostine↗
PubMed1985

B-cell lymphomas morphologically resembling T-cell lymphomas.

Seven cases of B-cell lymphoma that morphologically resembled T-cell lymphoma are described. These cases are of four morphologic types: atypical poorly differentiated lymphocytic lymphoma (PDLL) with convoluted nuclei, "Lennert's" lymphoma, mixed lymphocytic-"histiocytic" lymphoma with large variation in size of abnormal cells, and "histiocytic" lymphoma with large multilobed nuclei. These cases add further support to the belief that morphologic criteria alone are not sufficient for accurate immunologic classification of the malignant lymphomas since they may represent a distinct clinicopathologic entity.

B-Lymphocytes↗
PubMed1985

The uricosuric effect of oxaprozin in humans.

The effects of oxaprozin, a new investigational propionic acid analogue, and indomethacin on uric acid metabolism were compared in 12 healthy volunteers receiving either agent, first as a single dose and then daily for seven days. While indomethacin did not alter either serum or urinary uric acid values, oxaprozin caused a fall in serum uric acid levels from 5.8 +/- 0.2 mg/dL to 4.8 +/- 0.4 mg/dL (P less than 0.01). Urinary uric acid excretion rose from a baseline of 673 +/- 47 mg to 825 +/- 66 mg/24 h by day 7 of treatment (P less than 0.01). Since oxaprozin was associated with no change in glomerular filtration rate in these studies, the hypouricemic effect of oxaprozin is most likely a result of its direct uricosuric action. Because indomethacin and oxaprozin both are inhibitors of urinary prostaglandin E2 excretion, the data suggest that prostaglandin inhibition per se is not associated with changes in uric acid excretion.

Anti-Inflammatory Agents↗
PubMed1985

Bartter's syndrome: a unifying hypothesis.

The most proximate defect responsible for the pathogenesis of Bartter's syndrome remains uncertain. Although an abnormality in chloride reabsorption in the thick ascending limb of Henle has been postulated, renal clearance studies performed during oral water loading failed to disclose a reduction in fractional chloride reabsorption. We alternatively postulate that the underlying abnormality may reside in a generalized increase in cell sodium permeability. Elevated levels of cell sodium may secondarily stimulate Na-K-ATPase activity. In the cells of the distal nephron, stimulated Na-K-ATPase would lead to enhanced potassium secretion into the tubular fluid producing the characteristic potassium depletion. In addition, increased cell sodium influx may stimulate a sodium-calcium exchanger. If this process exists in vascular smooth muscle, it may result in reduction of cytosolic calcium activity. This effect and/or chronic potassium depletion may mediate the reduced vascular reactivity characteristic of this syndrome.

Adult↗
PubMed1985

Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.

S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR 2721) is a radio- and chemoprotective agent which produces hypocalcemia in humans. Intravenous injection of 30 mg/kg WR 2721 in rats and 15 mg/kg in dogs lowers serum calcium by 19 and 25%, respectively. Hypocalcemia in dogs is associated with a fall in serum immunoreactive parathyroid hormone (PTH), which suggests that the mechanism of its hypocalcemic effect is acute hypoparathyroidism. Despite this effect on PTH, in eight chronically parathyroidectomized rats on a low phosphate diet, WR 2721 reduced serum calcium from 9.4 +/- 0.6 to 7.7 +/- 0.5 mg/dl (P less than 0.01) at 3 h. Furthermore, in dogs rendered hypercalcemic by continuous infusion of PTH, WR 2721 reduced serum calcium from 11.0 +/- 0.5 to 10.6 +/- 0.5 mg/dl (P less than 0.01). To determine whether WR 2721 causes hypocalcemia by enhancing the exit of calcium from the circulation or inhibiting its entry, the drug was infused 3 h after administration of 45Ca to rats. WR 2721 did not significantly increase the rate of disappearance of 45Ca from the circulation even though serum calcium fell by 19%. However, serum 45Ca specific activity was higher at 1.5 h (P less than 0.01) and 3 h (P less than 0.05) in rats given WR 2721 than in rats given vehicle alone, which suggests that WR 2721 blocks the entry of nonradioactive calcium into the circulation, presumably from bone. In incubations with fetal rat long bone labeled in utero with 45Ca, 10(-3) M WR 2721 inhibited PTH-stimulated, but not base-line release of 45Ca. Bone resorption by primary culture of chick osteoclasts was inhibited by WR 2721 at concentrations as low as 10(-4) M in the absence of hormonal stimulation. These studies suggest that WR 2721 lowers serum calcium predominantly by blocking calcium release from bone. This acute hypocalcemic effect is at least in part independent of its effect on the parathyroid glands, and is most likely a direct effect of the agent on bone resorption.

Amifostine↗
PubMed1985

Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.

The chemoprotective and hypocalcemic agent WR-2721, S-2-(3-aminopropylamino) ethyl-phosphorothioic acid, inhibits parathyroid hormone secretion in vivo and in vitro. We report the first clinical use of WR-2721 in refractory hypercalcemia secondary to parathyroid cancer. After several days of saline diuresis the patient received WR-2721, 740 mg/m2 over 15 minutes, resulting in a fall in serum calcium from 11.76 to 9.06 mg/dL within 24 hours. Serum parathyroid hormone levels decreased from 675 to 140 microLeq/mL 2 hours after the infusion was complete. When hypercalcemia recurred the patient was retreated with differing doses and infusion rates to determine the optimal method of drug administration to provide a satisfactory hypocalcemic response without adverse effects. In this patient, WR-2721 in intravenous boluses of 150 mg/m2 was effective without adverse effects. Using high-pressure liquid chromatography with electrochemical detection, plasma pharmacokinetic studies showed that WR-2721's distribution half-life is 0.55 minutes.

Adenoma↗
PubMed1984

Hepatocellular injury, hyperplasia and putative premalignancy in rats fed 2-acetylaminofluorene.

Hepatocellular growth inhibition and restorative hyperplasia were studied in 80 young male Buffalo rats that were fed .02% 2-AAF for up to four weeks. Between 30 and 58 days of age, the control rats tripled their body weights and more than doubled their liver weights. But these increases were respectively inhibited by 25 and 22% in 2-AAF fed rats. Because the rats were in a phase of rapid growth, it was necessary to evaluate the age-related hepatic changes in control animals prior to analyzing the experimental data. Thirty-seven-day-old control rats had 3H-thymidine labeling indices of hepatocytes that were two to five times higher than in 58-day-old rats. A replicative gradient was also noted in the hepatic acini. At three ages of sacrifice (37, 44 and 58 days), the control hepatocytes in the periportal regions (Zone 1) had labeling indices that were at least three times higher than those surrounding the terminal hepatic veins (Zone 3). Histochemical GGTase activity also showed age-related zonal changes. Particularly prominent was the decrease with age in the enzyme activity of the most actively replicating Zone 1 hepatocytes. GGTase activity was observed in hepatocytes occupying 7.6% of tissue section areas in rats sacrificed at 30 days of age, but this decreased to 0.3% by the fourth week of the study. After four weeks of feeding the carcinogen toxic growth inhibition was most impressive in midzonal (Zone 2) hepatocytes, which also showed decreased glycogen, and decreased cytoplasmic RNA. The localization of injury to acinar midzones is particularly noteworthy in view of the extreme rarity of the finding in the hepatic toxicology literature. Growth inhibition was already apparent after only one week of 2-AAF feeding, when the 3H-thymidine labeling indices of Zone 2 hepatocytes were 90% lower (0.9%) than in control rats (8.6%). Hepatocellular hyperplasia, presumably a restorative response to the midzonal growth inhibition, was prominent in Zone 1, but also noted in Zone 3, after four weeks of the study. However, most of the Zone 1 hyperplastic cells showed canalicular GGTase activity, while none of the Zone 3 hyperplastic cells showed this phenotype. Occasional discrete foci of hyperplastic hepatocytes that were considered putatively premalignant because of their very high GGTase activity and low G6Pase and ATPase activities were also noted after four weeks of 2-AAF feeding. The foci were usually in close physical association with hyperplastic Zone 1 hepatocytes, but could be distinguished by their higher GGTase and lower G6Pase activities.(ABSTRACT TRUNCATED AT 400 WORDS)

2-Acetylaminofluorene↗
PubMed1984

Effects of isoproterenol on potassium secretion by the cortical collecting tubule.

These studies tested the effects of isoproterenol on potassium secretion in the isolated perfused cortical collecting tubule. Isoproterenol, 10(-6) M (n = 6) and 10(-4) M (n = 2), added to bathing solution produced a significant fall in potassium secretion [13.5 +/- 1.2 to 8.0 +/- 0.9 peq X mm-1 X min-1 (P less than 0.01)] and in transepithelial voltage (P less than 0.01) compared with time controls (n = 9). Pretreatment with propranolol abolished this effect (n = 4). Addition of propranolol alone to the bath caused no significant change in potassium secretion (n = 8). 8-[p-Chlorophenylthio]cAMP (10(-4) M, isotonic perfusate) added to the bath produced a significant fall in potassium secretion [11.5 +/- 1.7 to 7.2 +/- 1.3 peq X mm-1 X min-1, n = 7 (P less than 0.01)]. Arginine vasopressin (25 microU/ml), which also stimulates adenylate cyclase activity in this segment, had no significant effect on potassium secretion (n = 10). When chloride was replaced by methyl sulfate in all solutions (n = 6), there was a significant attenuation in the fall in potassium secretion in experiments with 10(-6) M isoproterenol compared with experiments with chloride-containing bath solutions (P less than 0.05). These data suggest that isoproterenol has a specific action of reducing potassium secretion in the cortical collecting tubule either through alternating chloride transport per se or through some other effect dependent on the presence of chloride (e.g., hydrogen ion secretion). Also, this effect is probably mediated by cAMP-dependent events. The lack of effect of vasopressin on potassium secretion suggests that separate cells or cellular pools of cAMP are involved in hormonal stimulation by isoproterenol and vasopressin in this nephron segment.

Animals↗
PubMed1984

Optimal use of sampled tissue sections for estimating the number of hepatocellular foci.

Statistical techniques were applied to computer-simulated data to evaluate the importance of various factors that may affect the estimation of the number of hepatocellular foci from foci transections. The simulations were modeled after mouse foci for which three-dimensional size distributions and densities were determined from serial section reconstructions. The foci had been induced in male C57BL/6 X C3H F1 mice at 20 and 28 weeks after a single injection, in infancy, of diethylnitrosamine. In an earlier report, we had shown that the number of foci per cu cm could be accurately estimated from profiles using a conditional estimator when the investigator is unable to identify profiles smaller than a certain size (epsilon). In the present study, emphasis was placed on assessing the value of step serial sections in order to make optimal use of the small tissue samples in mouse liver. Since all mathematical estimators of N3 are based on measurement of sampled profiles (n2') and ultimately derive from the fundamental relationship. N3' = N2'/2mu, (where N3' is the number of foci per cu cm, N2' is the number of profiles per sq cm, and mu, is the average adjusted focus radius), the relative importance of N2' and mu, on the conditional estimator was evaluated. This was accomplished by comparing the errors resulting from use of the conditional estimator with those resulting from use of two other estimators. The latter two estimators consisted of a "sampled focus estimator," which used sampled intact foci to estimate N3, and a "reference estimator," which used profiles from foci with a mu, that was known. Additionally, in order to provide a stable variance for the conditional estimator, we adopted a simple smoothing procedure. As expected, none of the estimators showed any significant bias. However, somewhat surprising was the finding that the standard deviations from use of all three estimators were almost identical. Consequently, it appears that the variance resulting from application of the smoothed conditional estimator to large sets of profile data is not due to difficulty in estimating mu epsilon. In these instances, the faulty estimates of N2' resulted almost entirely from the variability in sampling foci from tissue blocks which constituted only about 1/25 of the liver volume. In addition, the ability to reduce the error in estimating the number of foci by increasing the number of profiles was also evaluated. We simulated a sectioning protocol for the 28-week mouse livers in which the distances between the 5-micron-thick step sections in a 1-mm block of liver were progressively decreased from 1000 to 50 micron.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1983

Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent).

We investigated the causes of the hypocalcemia associated with WR-2721, an investigational drug that protects normal tissues against the toxic effects of radiation and chemotherapy. Sixteen patients with advanced cancers had serial measurements of serum calcium and other studies of blood chemistry before and after taking the compound. In all 16 patients (18 courses) the mean serum calcium level fell from 2.33 to 1.90 mmol per liter (9.33 to 7.62 mg per deciliter, P less than 0.001) after WR-2721, and in all 8 patients from whom data were obtained, serum calcium levels remained depressed at 24 hours. In 12 patients, ionized calcium levels dropped from 0.98 to 0.80 mmol per liter (P less than 0.01). Serum magnesium values fell from 0.96 to 0.74 mmol per liter (1.91 to 1.48 mg per deciliter, P less than 0.001). There were no changes in arterial pH or serum phosphate concentrations. In nine patients urinary calcium excretion rose from 3.96 to 10.68 mumol per minute (P less than 0.01) after WR-2721. Despite hypocalcemia, parathyroid hormone levels fell in all subjects. WR-2721 also inhibited the release of parathyroid hormone from bovine parathyroid cells incubated in vitro in low (0.5 mM) concentrations of calcium. We conclude that WR-2721 inhibits the secretion of parathyroid hormone and enhances calciuria, thereby leading to hypocalcemia.

Amifostine↗